While Stéphane Bancel received a lower-than-targeted bonus on the back of declining revenue and a missed sales goal, his total pay was still a record high. More: Moderna CEO Stéphane Bancel scored pay bump in 2024 despite revenue decline and
read moreAfter Novartis’ Pluvicto shook up iSpot.TV’s monthly rankings of the top TV advertising spenders in pharma to kick off the year, it was back to business as usual in February. More: AbbVie regained TV ad spending lead amid February slowdown,
read moreIn his third year as the CEO of Johnson & Johnson, Joaquin Duato received an overall compensation package of $24.3 million. It was a 14% decrease from his $28.4 million figure in 2023, when he was the highest-paid Big Pharma
read more
Phase 2a TREE study assesses safety and efficacy of leriglitazone More: Minoryx doses first patient with leriglitazone in Rett syndrome study Source: News
read more
Company seeks new direction after negative CHMP opinion on KIZFIZO More: Orphelia Pharma explores other pathways for paediatric cancer treatment Source: News
read moreAfter Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart—only once a year. More: A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase
read more© 1994 - 2026 B.M. Pharmaceuticals